<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753294</url>
  </required_header>
  <id_info>
    <org_study_id>PD-598654</org_study_id>
    <nct_id>NCT04753294</nct_id>
  </id_info>
  <brief_title>Confirm Safety and Performance of Avance Solo and Avance Solo Adapt NPWT Systems</brief_title>
  <acronym>ASOLO-CW</acronym>
  <official_title>A Prospective, Open, Non-comparative, Post-market Clinical Follow-up Investigation to Confirm the Safety and Performance of Avance Solo and Avance Solo Adapt NPWT Systems in Low to Moderate Exuding Chronic Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molnlycke Health Care AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntactx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Molnlycke Health Care AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this post market clinical follow-up (PMCF) investigation is to&#xD;
      confirm the safety and performance of Avance®Solo and Avance®Solo Adapt NPWT Systems in low&#xD;
      to moderate exuding chronic wounds when used in accordance with the Instructions for Use, for&#xD;
      up to 28 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This investigation is designed as a prospective, open and non-comparative PMCF investigation&#xD;
      to confirm the safety and performance of Avance®Solo and Avance®Solo Adapt in low to moderate&#xD;
      exuding chronic wounds. This is a multi-center study that will take place in approximately 5&#xD;
      European countries. The target subjects are male or female, 18 years or older with low to&#xD;
      moderate exuding chronic wounds (pressure ulcers (N=68), diabetic foot ulcers (N=34), and&#xD;
      venous leg ulcers (N=34)) suitable for NPWT as deemed by the investigator. Two different&#xD;
      options of Negative Pressure Wound Therapies (NPWT) will be evaluated through this clinical&#xD;
      investigation&#xD;
&#xD;
      A total of 136 subjects will receive treatment with the investigational devices within the&#xD;
      intended use according to Instructions for Use (IfU): Group 1: 102 subjects in total, 34&#xD;
      subjects per indication (pressure ulcers, diabetic foot ulcers, and venous leg ulcers)&#xD;
      treated with Avance®Solo and Group 2: 34 subjects with pressure ulcers treated with&#xD;
      Avance®Solo Adapt. Subjects will be managed and monitored for a maximum of 4 weeks or until&#xD;
      withdrawal from investigation for any reason.&#xD;
&#xD;
      The primary performance endpoint will include assessment of wound progress compared to last&#xD;
      visit during a maximum 28 days investigation period. Wound progression is determined by the&#xD;
      Investigator and will take into account all aspects of wound characteristics. Wound&#xD;
      progression will be assessed by the Investigator at each follow-up visit and measured by&#xD;
      three outcomes:&#xD;
&#xD;
        -  Deteriorated&#xD;
&#xD;
        -  No change&#xD;
&#xD;
        -  Improved&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2021</start_date>
  <completion_date type="Anticipated">March 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Four different patient groups treated with the Avance Solo NPWT System or Avance Solo Adapt NPWT System.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in wound progress</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Wound progress compared to last visit and assessed as:&#xD;
Deteriorated&#xD;
No change&#xD;
Improved</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound progress</measure>
    <time_frame>28 days</time_frame>
    <description>Wound progress compared between baseline and final visit and assessed as:&#xD;
Deteriorated&#xD;
No change&#xD;
Improved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in wound area</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Absolute change in wound area from baseline to all follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in wound volume</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Absolute change in wound volume from baseline to all follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in wound area</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Percentage change in wound area from baseline to all follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in wound volume</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Percentage change in wound volume from baseline to all follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue type</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Change in tissue type (slough, necrotic, granulation or epithelization) from baseline to all follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exudate amount</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Change in exudate amount using a category scoring system from baseline to all follow-up visits.&#xD;
Amount: none, low, moderate, or high)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exudate nature</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Change in exudate nature using a category scoring system from baseline to all follow-up visits.&#xD;
Nature: serous, fibrinous, serosanguineous, sanguineous, seropurulent, purulent, foul purulent, heamopurulent, or hemorrhagic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exudate odor</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Change in exudate odor using a category scoring system from baseline to all follow-up visits.&#xD;
Odor: no odor, slight, moderate, strong, and very strong</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-wound</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Change in peri-wound skin condition from baseline to all follow-up visits using the following conditions:&#xD;
Normal&#xD;
Erythematous&#xD;
Oedematous&#xD;
Eczematous&#xD;
Excoriated&#xD;
Macerated&#xD;
Indurated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue in-growth</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) with additional assessments in between when dressing is changed</time_frame>
    <description>Degree of tissue in-growth when Avance Solo foam is utilized at all follow-up visits as well as extra visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Subject evaluation of pain at Avance Solo dressing or Avance Solo Adapt Film removal using Numeric Rating Scale (NRS) at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trauma</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Proportion of subjects with trauma to the wound site and surrounding skin for Avance Solo Border Dressing, fixation strips or Avance Solo Adapt Film at all follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed using Numeric Rating Scale (NRS)</measure>
    <time_frame>28 days</time_frame>
    <description>Impact of everyday life by the systems will be captured through a NRS scale where the subject grade how much the treatment has affected the subject's daily life. 0 is equal to no influence and 10 to considerable influence on everyday life or unbearable.&#xD;
If replying &gt;0, the subject will state the presence or absence of the following causes:&#xD;
Leakage of dressing&#xD;
Impaired mobility&#xD;
Difficulties in getting dressed&#xD;
Pain&#xD;
Odor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alarms</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Subject evaluation of the system properties (number of sounding alarms) assessed with a given scale at all follow-up visits&#xD;
0&#xD;
1-5&#xD;
6-10&#xD;
11-15&#xD;
16-20&#xD;
More than 20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Evaluate the compliance to the provided therapy by average number of hours per 24h that the system has not provided treatment since last visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to absorb and/or transport exudate via clinical judgement</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Evaluation of the Systems ability to absorb and/or transport exudate assessed using a rating scale by the clinician/designee:&#xD;
Very Poor&#xD;
Poor&#xD;
Good&#xD;
Very Good</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of application</measure>
    <time_frame>Baseline, Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Clinician evaluation of ease of application and removal of Avance®Solo or Avance®Solo Adapt using a Numeric Rating Scale (NRS) collected at baseline, and each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global satisfaction</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluate the investigator and subject global satisfaction of the systems in regards to:&#xD;
Very dissatisfied&#xD;
Dissatisfied&#xD;
Neither satisfied or dissatisfied&#xD;
Satisfied&#xD;
Very satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product consumption</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Product consumption of the utilized products for the system's, from baseline and final visit using the Avance Solo or Avance Solo Adapt NPWT System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wear time</measure>
    <time_frame>Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)</time_frame>
    <description>Evaluate Avance®Solo or Avance®Solo Adapt wear time in days from baseline to all follow-up visits including potential extra visits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <condition>Pressure Ulcer</condition>
  <condition>Diabetic Foot Ulcer</condition>
  <condition>Chronic Ulcer</condition>
  <arm_group>
    <arm_group_label>Avance Solo NPWT System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with negative pressure wound therapy for Venous leg ulcers, Diabetic foot ulcers, and Pressure ulcers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avance Solo Adapt NPWT System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with negative pressure wound therapy for Pressure ulcers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Avance Solo NPWT System</intervention_name>
    <description>Wound treatment with Avance Solo NPWT System for up to 28 days.</description>
    <arm_group_label>Avance Solo NPWT System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Avance Solo Adapt NPWT System</intervention_name>
    <description>Wound treatment with Avance Solo Adapt NPWT System for up to 28 days.</description>
    <arm_group_label>Avance Solo Adapt NPWT System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥ 18 years.&#xD;
&#xD;
          2. Signed written informed consent.&#xD;
&#xD;
          3. Low to moderate exuding chronic wounds (diabetic foot ulcers, venous leg ulcers and&#xD;
             pressure ulcers for Avance®Solo or pressure ulcers for Avance®Solo Adapt) suitable for&#xD;
             NPWT according to the investigator´s judgement and Instructions for Use.&#xD;
&#xD;
          4. Subjects that will be capable and willing to comply with protocol instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known malignancy in the wound or margins of the wound&#xD;
&#xD;
          2. Untreated and previously confirmed osteomyelitis&#xD;
&#xD;
          3. Non-enteric and unexplored fistulas&#xD;
&#xD;
          4. Necrotic tissue with eschar present&#xD;
&#xD;
          5. Exposed nerves, arteries, veins or organs&#xD;
&#xD;
          6. Exposed anastomotic site&#xD;
&#xD;
          7. Known allergy/hypersensitivity to the dressing or its components.&#xD;
&#xD;
          8. Known pregnancy or planning to become pregnant or lactation at time of study&#xD;
             participation.&#xD;
&#xD;
          9. Participation in another investigative drug or device trial currently or within the&#xD;
             last 30 days Subjects not suitable for the investigation according to the&#xD;
             Investigator's judgement, Clinical Investigation Plan and Instructions for Use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hilde Beele, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tahmina Haider, MSc</last_name>
    <phone>0046739503674</phone>
    <email>tahmina.haider@molnlycke.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Sundh, PhD</last_name>
    <phone>0046739412816</phone>
    <email>daniel.sundh@molnlycke.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diensthoofd wondkliniek, UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hilde Beele, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hilde Beele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danneels, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nou Howaldt, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franziskus-Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berthold Amann, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik fur Dermatologie, Venerologie und Allergologie Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kerstin Kusch, DR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ruhr-Universität Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Stucker, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D08 NHY1</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary-Paula Colgan, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele S.r.I.</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Bertoglio, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Citta della Salute e della Scienza di Torino - A.O.U. Molinette San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio Verzini, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa casa da Misericórdia de Aveiro</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gomes Carlos Filipe, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidade de Cuidados Continuados António Francisco Guimarães</name>
      <address>
        <city>Guimarães</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vieira Nuna, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trofa Saúde Hospital Central Hospital da Trofa</name>
      <address>
        <city>Touguinho</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paulo Alves, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Portugal</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Negative Pressure Wound Therapy</keyword>
  <keyword>Post Market Clinical Follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Pressure Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diazepam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

